Gene A, a gene increased by mutant KRAS, is a potentially druggable target for lung adenocarcinoma

被引：0

作者：

Umeda, Kanna ^{[1
]}

Kawabe, Nozomi ^{[1
]}

Muraki, Nao ^{[1
]}

Komeda, Kazuki ^{[2
]}

Ohashi, Ayano ^{[1
]}

Katsuda, Masahito ^{[1
]}

Tomatsu, Aya ^{[1
]}

Yoshida, Mikina ^{[1
]}

Minna, John ^{[3
,4
]}

Tanaka, Ichidai ^{[2
]}

Morise, Masahiro ^{[2
]}

Matsushima, Miyoko ^{[1
]}

Kawabe, Tsutomu ^{[1
]}

Sato, Mitsuo ^{[1
]}

机构：

[1] Nagoya Univ, Div Host Def Sci, Dept Integrated Hlth Sci, Grad Sch Med, Nagoya, Aichi, Japan

[2] Nagoya Univ, Dept Resp Med, Grad Sch Med, Nagoya, Aichi, Japan

[3] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA

[4] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

来源：

RESPIROLOGY | 2024年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

AP04-003

引用

页码：91 / 91

页数：1

共 50 条

[1] Gene A, upregulated by mutant KRAS, is a potential therapeutic target for lung cancer
Kawabe, Nozomi
Muraki, Nao
Tanaka, Ichidai
Sunaga, Noriaki
Sato, Mitsuo
CANCER SCIENCE, 2024, 115 : 1547 - 1547
[2] Mutant KRAS is a druggable target for pancreatic cancer
Khvalevsky, Elina Zorde
Gabai, Racheli
Rachmut, Itzhak Haim
Horwitz, Elad
Brunschwig, Zivia
Orbach, Ariel
Shemi, Adva
Golan, Talia
Domb, Abraham J.
Yavin, Eylon
Giladi, Hilla
Rivkin, Ludmila
Simerzin, Alina
Eliakim, Rami
Khalaileh, Abed
Hubert, Ayala
Lahav, Maor
Kopelman, Yael
Goldin, Eran
Dancour, Alan
Hants, Yael
Arbel-Alon, Sagit
Abramovitch, Rinat
Shemi, Amotz
Galun, Eithan
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (51) : 20723 - 20728
[3] Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma
Dai, Dongjun
Shi, Rongkai
Han, Shuting
Jin, Hongchuan
Wang, Xian
MEDICINE, 2020, 99 (32)
[4] POTENTIALLY DRUGGABLE GENE ALTERATIONS IN GASTROINTESTINAL CANCER
Shibata, T.
ANNALS OF ONCOLOGY, 2014, 25
[5] Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
Soh, Junichi
Toyooka, Shinichi
Matsuo, Keitaro
Yamamoto, Hiromasa
Wistuba, Ignacio I.
Lam, Stephen
Fong, Kwun M.
Gazdar, Adi F.
Miyoshi, Shinichiro
ONCOLOGY LETTERS, 2015, 10 (03) : 1775 - 1782
[6] Novel driver gene ASAP2 is a potentially druggable target in pancreatic cancer
Masuda, Takaaki
Fujii, Atsushi
Iwata, Michio
Matsumoto, Yoshihiro
Otsu, Hajime
Takeishi, Kazuki
Yonemura, Yusuke
Yamanishi, Yoshihiro
Mimori, Koshi
CANCER SCIENCE, 2021, 112 : 276 - 276
[7] Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
Baldelli, Elisa
El Gazzah, Emna
Moran, John Conor
Hodge, Kimberley A.
Manojlovic, Zarko
Bassiouni, Rania
Carpten, John D.
Ludovini, Vienna
Baglivo, Sara
Crino, Lucio
Bianconi, Fortunato
Dong, Ting
Loffredo, Jeremy
Petricoin, Emanuel F.
Pierobon, Mariaelena
GENES, 2021, 12 (09)
[8] CFHR1 is a potentially downregulated gene in lung adenocarcinoma
Wu, Geting
Yan, Yuanliang
Wang, Xiang
Ren, Xinxin
Chen, Xi
Zeng, Shuangshuang
Wei, Jie
Qian, Long
Yang, Xue
Ou, Chunlin
Lin, Wei
Gong, Zhicheng
Zhou, Jianhua
Xu, Zhijie
MOLECULAR MEDICINE REPORTS, 2019, 20 (04) : 3642 - 3648
[9] Prognostic implications of EGFR and KRAS gene mutations in resected lung adenocarcinoma
Janjigian, Yelena Y.
Kris, Mark G.
Pao, William
Marks, Jenifer L.
Zheng, Junting
Shen, Ronglai
Dycoco, Joseph P.
Park, Bernard J.
Riely, Grey J.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S333 - S333
[10] Osteopontin drives KRAS-mutant lung adenocarcinoma
Giopanou, Ioanna
Kanellakis, Nikolaos, I
Giannou, Anastasios D.
Lilis, Ioannis
Marazioti, Antonia
Spella, Magda
Papaleonidopoulos, Vassilios
Simoes, Davina C. M.
Zazara, Dimitra E.
Agalioti, Theodora
Moschos, Charalampos
Magkouta, Sophia
Kalomenidis, Ioannis
Panoutsakopoulou, Vily
Lamort, Anne-Sophie
Stathopoulos, Georgios T.
Psallidas, Ioannis
CARCINOGENESIS, 2020, 41 (08) : 1134 - 1144

← 1 2 3 4 5 →